US005834596A

United States Patent [19]

Ageland et al.

[11] **Patent Number: 5,834,596**

[45] **Date of Patent: Nov. 10, 1998**

[54] **PROCESS FOR PURIFYING APOA OR APOE**

[75] Inventors: **Hans Ageland**, Bromma; **Lena Romander**, Nacka-Strand, both of Sweden

[73] Assignee: **Pharmacia & Upjohn AB**, Stockholm, Sweden

[21] Appl. No.: **875,125**

[22] PCT Filed: **Mar. 1, 1996**

[86] PCT No.: **PCT/SE96/00271**

§ 371 Date: **Jul. 17, 1997**

§ 102(e) Date: **Jul. 17, 1997**

[87] PCT Pub. No.: **WO96/27608**

PCT Pub. Date: **Sep. 12, 1996**

[30] **Foreign Application Priority Data**

Mar. 3, 1995 [SE] Sweden 9500778

[51] **Int. Cl.**[6] **C07K 1/00**; A23J 1/00; C12P 21/06

[52] **U.S. Cl.** **530/359**; 530/361; 530/402; 530/407; 530/409; 530/412; 530/416; 530/427; 514/2; 514/20; 514/21; 514/824; 435/69.1; 435/69.6; 424/406

[58] **Field of Search** 530/359, 350, 530/361, 402, 407, 409, 412, 416, 427; 514/2, 20, 21, 824; 435/69.1, 69.6; 424/406

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,059,528	10/1991	Bollen et al.	435/69.4
5,128,318	7/1992	Levine et al.	514/2

FOREIGN PATENT DOCUMENTS

0333474	9/1989	European Pat. Off. .
0494848	7/1992	European Pat. Off. .
0308336	3/1993	European Pat. Off. .
WO 88 03166	5/1988	WIPO .
WO8803166	5/1988	WIPO .
WO 90 12879	11/1990	WIPO .
WO 93 12143	6/1993	WIPO .
WO9312143	6/1993	WIPO .
WO 93 25581	12/1993	WIPO .
WO 94 13819	6/1994	WIPO .
WO9413819	6/1994	WIPO .

OTHER PUBLICATIONS

F.B. Anspach et al, Removal of Endotoxins by Affinity Sorbents. *Journal of Chromatography A,* 711 (1995) 81–92.

S. Minobe et al, Characteristics and Applications of Adsorbents for Pyrogen Removal. *Biotechnology and Applied Biochemistry* 10, 143–153 (1988).

H.B. Brewer et al, The Amino Acid Sequence of Human APOA–I, an Apolipoprotein Isolated from High Density Lipoproteins. *Biochemical and Biophysical Research Communications,80:3* (1978) 623–630.

J.P. Segrest et al, A Molecular Theory of Lipid–Protein Interations in the Plasma Lipoproteins. *FEBS Letters,* 38:3 (1974) 247–253.

G. Franceschini et al, A–IMilano Apoprotein: Decreased High Density Lipoprotein Cholesteral Levels with Significant Lipoprotein Modifications and Without Clinical Atherosclerosis in an Italian Family. *J Clin. Invest.* 66 (1980) 892–900.

K.H. Weisgraber et al, Apolipoprotein A–IMilano: Detection of Normal A–I in Affected Subjects and Evidence for a Cysteine for Arginine Substitut in the Variant A–I. *J. Biological Chemistry,* 258:4 (1983) 2508–2513.

G. Franceschini et al, Apoliporotein A–IMilano: Accelerated Binding and Disassociation from Lipids of a Human Apolipoprotein Variant. *J. Biological Chemistry,* 260:30 (1985) 16321–16325.

K. Emancipator et al, In Vitro Inactivation of Bacterial Endotoxin by Human Lipoproteins and Apolipoproteins. *Infection and Immunity,* 60:2 (1992) 596–601.

R. Munford, et al, Binding of *Salmonella Typhimurium* Lipopolysaccharides to Rat High–Density Lipoproteins. *Infection and Immunity, 34:3* (1981) 835–843.

T. Karplus et al, A new Method for Reduction of Endotoxin Contamination from Protein Solutions. *J. Immuno. Methods,* 105 (1987) 211–220.

C.R. Sirtori et al, Human Apolipoprotein Mutants III: Crystal Structures of the Common Apolipoprotein E Varients: Insights into Functional Mechanisms,. *NATO ASI Series,* Springer Verlag, Berlin, vol. II, 73–96 (1993).

Japio Abstract of JP61–96998 (1986).

Japio Abstract of JP1–95798 (1989).

Freudenberg et al (1979) *Nat. Toxins, Proc. Inc. Symp. Anim., Plant Microb. Toxins,* 6th Edition, pp. 349–354.

Gualandri et al (1985), *Am. J. Hum. Genet,* vol. 37, pp. 1083–1097.

(List continued on next page.)

Primary Examiner—Cecilia J. Tsang
Assistant Examiner—Abdel A. Mohamed
Attorney, Agent, or Firm—Dinsmore & Shohl LLP

[57] **ABSTRACT**

A process for purifying apolipoprotein A (ApoA) or apolipoprotein E (ApoE), or variants or mixtures thereof, comprises contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix. Alternatively, the process comprises contacting the first aqueous solution comprising ApoA or ApoE and endotoxins with an anion-exchange matrix for attaching the ApoA and ApoE to the matrix, treating the anion-exchange matrix with a second aqueous solution comprising a compound comprising two or three nitrogen atoms bonded to a carbon atom for releasing the endotoxins while the ApoA or ApoE remains attached to the matrix, and then releasing the ApoA or ApoE from the matrix.

30 Claims, No Drawings